Details
Stereochemistry | UNKNOWN |
Molecular Formula | C21H22N2O3 |
Molecular Weight | 350.411 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12C[C@@]3([H])C4=CCO[C@@]5([H])CC(=O)N6C7=C(C=CC=C7)[C@@]1(CC[N+]2([O-])C4)[C@]6([H])[C@@]35[H]
InChI
InChIKey=ADTDBAKUQAKBGZ-VXJIXCKJSA-N
InChI=1S/C21H22N2O3/c24-18-10-16-19-13-9-17-21(6-7-23(17,25)11-12(13)5-8-26-16)14-3-1-2-4-15(14)22(18)20(19)21/h1-5,13,16-17,19-20H,6-11H2/t13-,16-,17-,19-,20-,21+,23?/m0/s1
Molecular Formula | C21H22N2O3 |
Molecular Weight | 350.411 |
Charge | 0 |
Count |
|
Stereochemistry | EPIMERIC |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 7 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Strychnine-N-oxide is the major metabolite of Strychnine. Strychnine, the major alkaloid present in $trychnos:nuxypmicagseeds has been reported to stimulate
the entire central nervous system with preference for the
spinal cord. It is a powerful convulsant and because of
this property, it is an important pharmacological tool as
it plays a unique role as an inhibitor of post synaptic
inhibitory impulses. It is useful to study inhibitory
transmitter and receptor types. However, because of its
extreme toxicity, strychnine does not have any therapeutic
application in the Western system of medicine. Strychnine-N-oxide is less toxic and less convulsive than strychnine itself. However, strychnine N-oxide is not
being used as a therapeutic agent now probably because of the threat of convulsions at higher doses. Strychnine-N-oxide is a muscarinic allosteric agent.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL211 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9986715 |
|||
Target ID: CHEMBL216 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9986715 |
|||
Target ID: CHEMBL245 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9986715 |
|||
Target ID: CHEMBL1821 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9986715 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Concise Syntheses of bis-Strychnos Alkaloids (-)-Sungucine, (-)-Isosungucine, and (-)-Strychnogucine B from (-)-Strychnine. | 2016 Aug 8 |
|
Determination of strychnine, brucine, strychnine N-oxide, and brucine N-oxide in plasma samples after the oral administration of processed semen strychni extract by high-performance liquid chromatography with ultrasound-assisted mixed cloud point extraction. | 2016 Jul |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.drugfuture.com/toxic/q127-q978.html
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE: Subcutaneous
SPECIES OBSERVED: Rodent - mouse
DOSE/DURATION: 24500 ug/kg
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9986715
Binding affinity at the NMS liganded human muscarinic acetylcholine receptor M1 was estimated as log affinity (log1/M) = 3.8.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 01:37:38 GMT 2023
by
admin
on
Sat Dec 16 01:37:38 GMT 2023
|
Record UNII |
774C760V46
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
774C760V46
Created by
admin on Sat Dec 16 01:37:38 GMT 2023 , Edited by admin on Sat Dec 16 01:37:38 GMT 2023
|
PRIMARY | |||
|
230-656-5
Created by
admin on Sat Dec 16 01:37:38 GMT 2023 , Edited by admin on Sat Dec 16 01:37:38 GMT 2023
|
PRIMARY | |||
|
127569
Created by
admin on Sat Dec 16 01:37:38 GMT 2023 , Edited by admin on Sat Dec 16 01:37:38 GMT 2023
|
PRIMARY | |||
|
24951
Created by
admin on Sat Dec 16 01:37:38 GMT 2023 , Edited by admin on Sat Dec 16 01:37:38 GMT 2023
|
PRIMARY | |||
|
73393
Created by
admin on Sat Dec 16 01:37:38 GMT 2023 , Edited by admin on Sat Dec 16 01:37:38 GMT 2023
|
PRIMARY | |||
|
m10256
Created by
admin on Sat Dec 16 01:37:38 GMT 2023 , Edited by admin on Sat Dec 16 01:37:38 GMT 2023
|
PRIMARY | Merck Index | ||
|
7248-28-4
Created by
admin on Sat Dec 16 01:37:38 GMT 2023 , Edited by admin on Sat Dec 16 01:37:38 GMT 2023
|
PRIMARY | |||
|
132703
Created by
admin on Sat Dec 16 01:37:38 GMT 2023 , Edited by admin on Sat Dec 16 01:37:38 GMT 2023
|
PRIMARY | |||
|
DTXSID80993305
Created by
admin on Sat Dec 16 01:37:38 GMT 2023 , Edited by admin on Sat Dec 16 01:37:38 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SOLVATE->ANHYDROUS |